TAO Synergies Net Income Over Time
| TAOX Stock | 3.94 0.22 5.91% |
With this module, investors can use any or all of fundamental ratio historical patterns as a complementary method for asset selection as well as a tool for deciding entry and exit points. Many technical investors use fundamentals to limit their universe of possible portfolio assets.
Check out TAO Synergies Performance and TAO Synergies Correlation. Is Systems Software space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of TAO Synergies. If investors know TAO will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. Comprehensive TAO Synergies assessment requires weighing all these inputs, though not all factors influence outcomes equally.
Investors evaluate TAO Synergies using market value (trading price) and book value (balance sheet equity), each telling a different story. Calculating TAO Synergies' intrinsic value - the estimated true worth - helps identify when the stock trades at a discount or premium to fair value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. External factors like market trends, sector rotation, and investor psychology can cause TAO Synergies' market price to deviate significantly from intrinsic value.
Please note, there is a significant difference between TAO Synergies' value and its price as these two are different measures arrived at by different means. Investors typically determine if TAO Synergies is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. Conversely, TAO Synergies' market price signifies the transaction level at which participants voluntarily complete trades.
Cross Equities Net Income Analysis
Compare TAO Synergies and related stocks such as Sonnet Biotherapeutics, Rallybio Corp, and Plus Therapeutics Net Income Over Time
Select Fundamental| 2010 | 2011 | 2012 | 2013 | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| RLYB | (17.6 M) | (17.6 M) | (17.6 M) | (17.6 M) | (17.6 M) | (17.6 M) | (17.6 M) | (17.6 M) | (17.6 M) | (17.6 M) | (26.4 M) | (47 M) | (66.7 M) | (74.6 M) | (57.8 M) | (52 M) | (54.6 M) |
| PSTV | (2.1 M) | (32.5 M) | (32.3 M) | (26.2 M) | (37.4 M) | (18.7 M) | (22 M) | (22.7 M) | (12.6 M) | (10.9 M) | (8.2 M) | (13.4 M) | (20.3 M) | (13.3 M) | (13 M) | (11.7 M) | (12.3 M) |
| INTS | (5.2 M) | (5.2 M) | (5.2 M) | (5.2 M) | (5.2 M) | (5.2 M) | (5.2 M) | (5.2 M) | (5.2 M) | (5.2 M) | (6 M) | (7.9 M) | (7.6 M) | (10.5 M) | (16.3 M) | (14.6 M) | (13.9 M) |
| IBIO | (1.7 M) | (5.7 M) | (6.2 M) | (3.7 M) | (6.6 M) | (9.8 M) | (14.5 M) | (16.1 M) | (17.6 M) | (16.4 M) | (23.2 M) | (50.4 M) | (29.3 M) | (24.9 M) | (18.4 M) | (16.5 M) | (17.4 M) |
| BOLD | (59.7 M) | (59.7 M) | (59.7 M) | (59.7 M) | (59.7 M) | (59.7 M) | (59.7 M) | (90.2 M) | (128.8 M) | (25.2 M) | (25.2 M) | (25.2 M) | (45.9 M) | (49.4 M) | (65.4 M) | (75.2 M) | (78.9 M) |
| NXTC | (15.5 M) | (15.5 M) | (15.5 M) | (15.5 M) | (15.5 M) | (15.5 M) | (15.5 M) | (15.5 M) | (22.8 M) | (33.7 M) | (33.2 M) | (69.4 M) | (69.4 M) | (62.7 M) | (55.7 M) | (50.1 M) | (52.6 M) |
| KLTO | (913) | (913) | (913) | (913) | (913) | (913) | (913) | (913) | (913) | (913) | (913) | (1.1 M) | (598.6 K) | (707.5 K) | (6.2 M) | (5.5 M) | (5.3 M) |
| ITRM | (13.5 M) | (13.5 M) | (13.5 M) | (13.5 M) | (13.5 M) | (13.5 M) | (13.5 M) | (29.4 M) | (77.1 M) | (103.1 M) | (52 M) | (91.6 M) | (44.4 M) | (38.4 M) | (24.8 M) | (28.5 M) | (29.9 M) |
| CVKD | (6.7 M) | (6.7 M) | (6.7 M) | (6.7 M) | (6.7 M) | (6.7 M) | (6.7 M) | (6.7 M) | (6.7 M) | (6.7 M) | (6.7 M) | (6.7 M) | (6.7 M) | (8.4 M) | (10.7 M) | (9.6 M) | (10.1 M) |
TAO Synergies and related stocks such as Sonnet Biotherapeutics, Rallybio Corp, and Plus Therapeutics Net Income description
Net income is one of the most important fundamental items in finance. It plays a large role in TAO Synergies financial statement analysis. It represents the amount of money remaining after all of TAO Synergies operating expenses, interest, taxes and preferred stock dividends have been deducted from a company total revenue.My Equities
My Current Equities and Potential Positions
| TAO Synergies | TAOX |
Specialization | Information Technology, Software - Infrastructure |
| Business Address | 1185 Avenue of |
| Exchange | NASDAQ Exchange |
null 3.94
Additional Tools for TAO Stock Analysis
When running TAO Synergies' price analysis, check to measure TAO Synergies' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy TAO Synergies is operating at the current time. Most of TAO Synergies' value examination focuses on studying past and present price action to predict the probability of TAO Synergies' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move TAO Synergies' price. Additionally, you may evaluate how the addition of TAO Synergies to your portfolios can decrease your overall portfolio volatility.